Elisabetta Patorno
Overview
Explore the profile of Elisabetta Patorno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
188
Citations
3101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tesfaye H, Paik J, Zakoul H, Schmedt N, Wexler D, Patorno E
Diabetes Obes Metab
. 2025 Feb;
PMID: 40019137
No abstract available.
2.
Ray A, Paik J, Wexler D, Sreedhara S, Bykov K, Feldman W, et al.
JAMA Intern Med
. 2025 Feb;
PMID: 39928303
Importance: Recent studies have suggested that sodium-glucose cotransporter-2 inhibitors (SGLT-2is), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase 4 inhibitors (DPP-4is) may benefit patients with chronic obstructive pulmonary disease (COPD)....
3.
Hansrivijit P, Tesfaye H, Wexler D, Abdi R, Patorno E, Paik J
J Clin Med
. 2025 Jan;
14(2.
PMID: 39860655
To date, there are limited studies describing the use of glucose-lowering medications (GLMs) in adult kidney transplant recipients (KTRs), and the uptake of sodium glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like...
4.
Shin H, Paik J, Everett B, DiCesare E, Alix C, Glynn R, et al.
JAMA Intern Med
. 2025 Jan;
185(3):302-313.
PMID: 39836397
Importance: Evidence on cardiovascular benefits and safety of sodium-glucose cotransporter 2 (SGLT-2) inhibitors is mainly from placebo-controlled trials. Therefore, the comparative effectiveness and safety of individual SGLT-2 inhibitors remain unknown....
5.
Kutz A, Kim D, Liu J, Munshi M, Patorno E
Diabetes Care
. 2025 Jan;
48(3):455-463.
PMID: 39746144
Objective: To assess prescribing trends of glucose-lowering medications in the last year of life among older adults with type 2 diabetes (T2D) and explore whether frailty is associated with differential...
6.
Tesfaye H, Paik J, Roh M, Htoo P, Zakoul H, Schmedt N, et al.
JAMA Ophthalmol
. 2024 Dec;
143(1):62-71.
PMID: 39636645
Importance: Empagliflozin might lower the risk of diabetic retinopathy (DR) by preventing retinal pericyte loss. However, the role of empagliflozin with respect to DR in patients with type 2 diabetes...
7.
Wang E, Patorno E, Khosrow-Khavar F, Crystal S, Dave C
Diabetologia
. 2024 Nov;
68(1):94-104.
PMID: 39514094
Aims/hypothesis: The aim of this study was to investigate racial and ethnic disparities in the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor antagonists (GLP-1RAs) among older...
8.
9.
Alkabbani W, Suissa K, Gu K, Cromer S, Paik J, Bykov K, et al.
BMJ
. 2024 Oct;
387:e080340.
PMID: 39438043
Objective: To assess whether use of glucagon-like peptide-1 (GLP-1) receptor agonists before upper gastrointestinal endoscopy is associated with increased risk of pulmonary aspiration or discontinuation of the procedure compared with...
10.
Yland J, Huybrechts K, Wesselink A, Straub L, Chiu Y, Seely E, et al.
Diabetes Care
. 2024 Jul;
47(9):1688-1695.
PMID: 39042587
Objective: We emulated a modified randomized trial (Metformin in Women With Type 2 Diabetes in Pregnancy [MiTy]) to compare the perinatal outcomes in women continuing versus discontinuing metformin during pregnancy...